Predictors of recurrence, early treatment failure and death from Staphylococcus aureus bacteraemia: Observational analyses within the ARREST trial. Issue 4 (October 2019)

• Record Type: Journal Article
• Authors: Szubert, Alexander; Bailey, Sarah Lou; Cooke, Graham S.; Peto, Tim; Llewelyn, Martin J.; Edgeworth, Jonathan D.; Walker, A. Sarah; Thwaites, Guy E.
• Is Part Of: Journal of infection. Volume 79:Issue 4(2019)
• Page Start: 332
• Page End: 340
• Publication Date: 2019-10
• Subjects: Bacteraemia -- Staphylococcus aureus -- Mortality -- Recurrence -- Rifampicin; Infection -- Periodicals; Bacterial Infections -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.905
• DOI: 10.1016/j.jinf.2019.08.001
• Languages: English
• ISSNs: 0163-4453

Abstract

Highlights: Recurrence strongly associated with liver and renal failure, diabetes and immune-suppressive drugs. A persistent focus was judged the primary reason for recurrence in 23(74%). A risk score based on BMI, Immunosuppression, Renal disease, Diabetes, Liver disease predicted recurrence. Older age and higher neutrophil counts predicted early treatment failure and S. aureus-attributed mortality. Abstract: Objectives: Adjunctive rifampicin did not reduce failure/recurrence/death as a composite endpoint in the ARREST trial of Staphylococcus aureus bacteraemia, but did reduce recurrences. We investigated clinically-defined 14-day treatment failure, and recurrence and S. aureus -attributed/unattributed mortality by 12-weeks to further define their predictors. Methods: A post-hoc exploratory analysis using competing risks models was conducted to identify sub-groups which might benefit from rifampicin. A points-based recurrence risk score was developed and used to compare rifampicin's benefits. Results: Recurrence was strongly associated with liver and renal failure, diabetes and immune-suppressive drugs ( p < 0.005); in contrast, failure and S. aureus -attributed mortality were associated with older age and higher neutrophil counts. Higher SOFA scores predicted mortality; higher Charlson scores and deep-seated initial infection focus predicted failure. Unexpectedly, recurrence risk increased with increasing BMI in placebo ( p = 0.04) but not rifampicin ( p = 0.60) participants (pheterogeneity = 0.06). A persistent focus was judged the primary reason for recurrence in 23(74%). A 5-factor risk score based on BMI, Immunosuppression, Renal disease, Diabetes, Liver disease (BIRDL) strongly predicted recurrence ( p < 0.001). Conclusions: Rifampicin reduces recurrences overall; those with greatest absolute risk reductions were identified using a simple risk score. Source control and adequate duration of antibiotic therapy remain essential to prevent recurrence and improve outcomes.